期刊文献+

骨化三醇冲击联合树脂吸附治疗严重继发性甲状旁腺功能亢进症

Calcitriol pulse therapy combined with resin adsorption in treatment of severe secondary hyperparathyroidism
原文传递
导出
摘要 目的 探讨骨化三醇冲击联合树脂吸附治疗严重继发性甲状旁腺功能亢进症的疗效.方法 将32例血液透析患者采用随机数字表法分为骨化三醇冲击组(CP组)12例、骨化三醇冲击联合树脂吸附组(CP+RA组)10例和树脂吸附组(RA组)10例.治疗前及治疗后1、2、3个月测定血清免疫反应性甲状旁腺素(iPTH)、白蛋白、尿素、肌酐和血红蛋白.每半个月测定血钙、磷.结果 每次树脂吸附后较吸附前iPTH明显下降(P〈0.05).CP+RA组治疗后2个月iPTH水平较治疗前明显下降,治疗后3个月,CP+RA组iPTH水平为(598.50±317.45)ne/L,明显低于CP组的(1008.67±436.85)ng/L和RA组的(1464.60±411.27)ng/L (P〈0.05).结论 骨化三醇冲击联合树脂吸附能有效降低严重继发性甲状旁腺功能亢进症患者的iPTH水平. Objective To investigate the effects of oral calcitriol pulse therapy combined with resin adsorption in treatment of severe secondary hyperparathyroidism.Methods Thirty-two hemodialysis patinents were randomly divided into three groups:oral calcitriol pulse therapy(CP group,12 cases),oral calcitriol pulse therapy combined with resin adsorption group(CP+RA group,10 cases),and resin adsorption group(RA group,10 cases).Serum immunoreactive parathyroid hormone(iPTH),albumin,urea,creatinine,hemoglobin levels were detected before treatment and 1,2,3 months after treatment respectively.Serum calcium and phosphorus levels were also detected every half a month.Results The clearance rate of resin adsorption Was decreased significantly every time(P〈0.05).Serum iPTH in CP+RA group decreased significantly 2 months after treatment.Serum iPTH3 months after treatment in CP+RA group[(598.50 ±317.45)ng/L]was less than that in CP group[(1008.67±436.85)ng/L]and RA group[(1464.60±411.27)ns/L](P〈0.05).Conclusion Oral calcitriol pulse therapy combined with resin adsorption can clear iPTH safely and effectively.
出处 《中国医师进修杂志》 2010年第16期5-7,共3页 Chinese Journal of Postgraduates of Medicine
关键词 骨化三醇 甲状旁腺功能亢进症 继发性 树脂吸附 Calcitriol Hyperparathyroidism,secondary Resin adsorption
  • 相关文献

参考文献9

  • 1王成,娄探奇,陈珠江,唐骅,石成钢,余学清.树脂吸附对慢性肾衰维持性血液透析患者血清甲状旁腺素的影响(英文)[J].中国现代医学杂志,2004,14(21):22-24. 被引量:3
  • 2卞维静,王国勤,罗洋,付芳婷,张凌,李文歌,谌贻璞.长期血液透析患者继发性甲状旁腺功能亢进症的流行病学分析[J].中日友好医院学报,2008,22(4):195-197. 被引量:37
  • 3Kidney Disease:Improving Global Outcomes(KDIGO)CKD-MBD Work Group.KDIGO Clinical Practice Guideline for the diagnosis,evaluation,prevention,and treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD).Kidney Int,2009,76Suppl 113:S70-89.
  • 4Cozzolino M,Galassi A,Gallieni M,et al.Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients:the role of paricalcitol.Curr Vase Pharmacol,2008,6(2):148-153.
  • 5London GM,Marry C,Marcbals SJ,et al.Arterial calcifications and bone histomorphometry in end-stage renal disease.J Am Soc Nephrol,2004,15(7):1943-1951.
  • 6Brancaccio D,Cozzolino M,Gallleni M.Hyperparathyroidism and anemia in uremic subjects:a combined therapeutic approach.J Am Soc Nephrol,2004,15 Suppl 1:S21-24.
  • 7Premaor MO,Scalco R,da Silva MJ,et al.Secondary hyperparathyroidism is associated with increased risk of hospitalization Or death in elderly adults living in a geriatric institution.Gerontology,2009,55(4):405-410.
  • 8Taniguchi M,Tokumoto M,Matsuo D,et al.Parathyroid growth and regression in experimental uremia.Kidney Int,2006,69(3):464-470.
  • 9刘俊,刘志强,陶惠琴.血液净化对慢性肾功能衰竭患者全段甲状旁腺激素的影响[J].第一军医大学学报,2004,24(2):234-235. 被引量:42

二级参考文献17

  • 1徐启河,刘平,李惊子,黄颖,冷炜,韩秀菊,申洪征.三种甲旁腺激素测定在血液透析患者的意义[J].北京医科大学学报,1994,26(4):287-288. 被引量:1
  • 2孙鲁英,王梅,杨莉.终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J].北京大学学报(医学版),2005,37(2):147-150. 被引量:63
  • 3周福德,王梅.北京市血液透析的发展与质量改进[J].中国血液净化,2006,5(3):117-118. 被引量:56
  • 4WANG HJ. New conception of uremic toxin. Foreign Medical Sciences[J]. Section of Nephrology, 2002,22(3): 136-137. Chinese
  • 5CHENG H, ZOU ZJ, CHEN JM, et al. The clearance effect of hemodialysis with highly permeable dialyzer on parathyroid hormone [J]. Chinese Joural of Blood Purification, 2000, 1 (3): 186 -187. Chinese
  • 6Kucharska E, Stompor T, Salowicz W, et al. Renal osteodystrophy in dialysis patients as estimated by three point bone densitometry [J]. Prezgl Lek, 2000, 57(6): 334.
  • 7Lugon JR, Andre ME, Duarte ME, et al. Effects of in center daily hemodialysis upon mineral metabolism and bone disease in end stage renal disease patients[J]. Sao Paulom Med J, 2001, 119(3): 105.
  • 8Liach F. Calcifif uremic arteriopathy: An evolving entity[J] ? Am J Kidney, 1998, 32:514-518.
  • 9Horl WH.The clinical consequences of secondary hyperparathyroidism:focus on clinical outcomes [J].Nephrol Dial Thansplant, 2004,19 (suppl 5):V2-V8.
  • 10National Kidney Foundation.K/DOQI clinical practice guidlines for bone metabolism and disease in chronic kidney disease[J].Am J Kidney dis,2003,42:S1-S202.

共引文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部